Calcitonin Injection Market Growth Through 2030 Creates New Strategic Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Calcitonin Injection Market Size Forecast: How Large Could The Market Become By 2030?
The calcitonin injection market has experienced strong expansion in recent years, with projections showing an increase from $0.73 billion in 2025 to $0.79 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.4%. Factors driving growth during the historical period include the high prevalence of osteoporosis, the use of injectable therapies in hospital settings, established protocols for fracture management, disorders related to calcium metabolism, and the rising number of elderly individuals in the population.
Over the upcoming years, the calcitonin injection market is anticipated to experience robust expansion. By 2030, its value is projected to reach $1.07 billion, reflecting a compound annual growth rate (CAGR) of 8.1%. This forecasted growth is driven by factors such as the rising elderly population, increasing demand for injectable treatments, heightened awareness of bone diseases, progress in synthetic peptide development, and the broadening of specialty care services. Key developments shaping this period include the sustained application of calcitonin in osteoporosis management, the growing prevalence of injectable therapies for bone conditions, an expanded role in treating hypercalcemia, a stronger emphasis on skeletal health among older adults, and a transition toward synthetic formulations of calcitonin.
Download A Free Sample Report For Comprehensive Market Insights:
Calcitonin Injection Market Development Factors: Which Trends Are Supporting Demand?
The rising occurrence of osteoporosis is forecasted to boost the calcitonin injection market in the coming years. This medical condition involves reduced bone density and a higher likelihood of fractures, commonly seen in older individuals, particularly those who are postmenopausal women. The growing number of cases can be attributed to an aging demographic, where extended lifespans result in natural bone density decline and an elevated disease risk. Calcitonin injections aid in osteoporosis management by regulating calcium levels and decelerating bone loss, thus proving effective in preserving bone density. This approach offers targeted intervention through simple-to-administer shots, which enhances patient adherence and lowers fracture risks. As an example, in August 2024, Healthy Bones Australia, a nonprofit organization dedicated to bone health and osteoporosis prevention, reported that in 2023, an estimated 6.2 million Australians aged 50 and above, equating to roughly 67% of that demographic, suffered from poor bone health, with about 23% of these individuals affected by osteoporosis. Consequently, the increasing prevalence of osteoporosis is fueling expansion in the calcitonin injection market.
The growth of home healthcare services is anticipated to drive forward the calcitonin injection market in the future. These services encompass medical support and care provided to patients within their own homes by qualified healthcare practitioners. Their expansion is being fueled by a growing movement of patients away from hospital environments toward home-based care, which lowers overall treatment expenses while enhancing comfort and ease of access. As home healthcare services rapidly broaden, the calcitonin injection market is seeing heightened demand, prompting providers to embrace injectable therapies suited for at-home management of ailments like osteoporosis and acute pain. By way of illustration, according to the National Association for Home Care and Hospice, a US nonprofit advocating for chronically ill, disabled, and dying Americans, roughly 12 million individuals in the United States receive some form of home healthcare annually, a figure predicted to increase further. Hence, the broadening of home healthcare services is propelling growth in the calcitonin injection market.
Calcitonin Injection Market Segmentation: How Is The Market Structured Across Key Categories?
The calcitonin injection market covered in this report is segmented –
1) By Type Of Calcitonin: Salmon Calcitonin, Human Calcitonin, Synthetic Calcitonin
2) By Route Of Administration: Intravenous (IV) Injection, Subcutaneous Injection, Intramuscular Injection
3) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Healthcare Institutions
4) By Therapeutic Application: Osteoporosis Treatment, Pagets Disease Management, Hypercalcemia Control, Bone Metastases Therapy
5) By End-User: Hospitals, Specialty Clinics, Geriatric Care Facilities, Home Healthcare
Subsegments:
1) By Salmon Calcitonin, Synthetic Salmon Calcitonin, Recombinant Salmon Calcitonin
2) By Human Calcitonin, Recombinant Human Calcitonin, Synthetic Human Calcitonin
3) By Synthetic Calcitonin, Peptide-Based Synthetic Calcitonin, Analog Synthetic Calcitonin
Calcitonin Injection Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the calcitonin injection sector are increasingly dedicating resources to the creation of advanced products, such as USP synthetic injections, aimed at boosting therapeutic efficacy and improving patient recovery rates. A USP Synthetic Injection is defined as a medication for injection that features synthetically derived active ingredients conforming to the rigorous specifications for quality, purity, potency, and identity established by the United States Pharmacopeia (USP). These injections are produced under stringent, regulated manufacturing processes to guarantee their safety and effectiveness for medical applications. As a case in point, in February 2025, Fresenius Kabi, a pharmaceutical firm headquartered in Germany, introduced a calcitonin salmon injection—classified as a USP synthetic—designed for the management of symptomatic Paget’s disease of bone and hypercalcemia. This product is a sterile solution intended for administration via intramuscular or subcutaneous routes, provided at a concentration of 200 USP units per mL and supplied in a 2 mL multi-dose vial with a total of 400 USP units. Storage requirements specify refrigeration within a temperature range of 2°C to 8°C. Serving as a calcium-regulating agent, this injectable drug is prescribed for symptomatic Paget’s disease of bone where alternative therapies are not viable, hypercalcemia, and postmenopausal osteoporosis in cases where other options are inadequate.
Calcitonin Injection Market Competitive Landscape And Leading Companies
Major companies operating in the calcitonin injection market are Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Intas Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Wockhardt Limited, Accord Healthcare Ltd., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Mylan N.V., Cadila Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Bharat Parenterals Limited
Access The Complete Calcitonin Injection Market Report:
Calcitonin Injection Market Geographic Distribution And Regional Opportunities
North America was the largest region in the calcitonin injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
